| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
11,886 |
11,145 |
$710K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
4,060 |
4,051 |
$361K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,884 |
5,603 |
$332K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,342 |
1,340 |
$126K |
| 99051 |
|
4,202 |
4,040 |
$70K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,696 |
1,638 |
$40K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,371 |
1,309 |
$29K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
394 |
377 |
$16K |
| 81025 |
|
839 |
810 |
$5K |
| 81002 |
|
1,566 |
1,512 |
$5K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
152 |
150 |
$5K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
74 |
71 |
$2K |
| 87430 |
|
98 |
98 |
$1K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
186 |
175 |
$1K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
55 |
55 |
$893.47 |
| 86580 |
|
29 |
28 |
$252.59 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
88 |
86 |
$220.93 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
15 |
15 |
$109.89 |
| 94760 |
|
18 |
18 |
$49.47 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
75 |
72 |
$27.23 |